For the second quarter of FY2023 ending June 30 2023, INCYTE CORPORATION ($NASDAQ:INCY) reported total revenue of USD 954.6 million, an increase of 4.7% compared to the same period of the prior year. Additionally, net income for the quarter rose 26.1% to USD 203.6 million.
An analysis of Incyte’s financials with GoodWhale reveals a strong health score of 8/10 in cashflows and debt, indicating that the company is capable of paying off debt and funding future operations. Incyte is classified as a “Rhino” stock, a type of company that has achieved moderate revenue or earnings growth. Given the company’s solid financial standing, investors looking for growth opportunities may be interested in Incyte. The Star Chart shows that Incyte is strong in asset, growth, profitability, and weak in dividend. Thus, investors looking for long-term capital appreciation may be more likely to invest in Incyte than those looking for dividend income. Overall, Incyte seems to be a sound investment choice for those seeking growth opportunities. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Incyte Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Incyte Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Incyte Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Incyte Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Incyte Corp’s main competitors are Jazz Pharmaceuticals PLC, Amplia Therapeutics Ltd, CanBas Co Ltd. All of these companies are in the business of developing and selling drugs. Incyte Corp’s main competitors are all much larger companies, with Jazz Pharmaceuticals PLC having the largest market capitalization at $13.4 billion. Incyte Corp’s main competitors are all much older companies, with Amplia Therapeutics Ltd being the oldest, founded in 1998.
– Jazz Pharmaceuticals PLC ($NASDAQ:JAZZ)
Jazz Pharmaceuticals PLC is a biopharmaceutical company that focuses on improving patient’s lives by developing and commercializing products that address unmet medical needs. The company has a market cap of 9.13B and a return on equity of 4.24%. Jazz Pharmaceuticals PLC is a global company with operations in the United States, Europe, and Canada. The company’s products are available in over 60 countries.
– Amplia Therapeutics Ltd ($ASX:ATX)
Amplia Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for patients with serious or life-threatening diseases. The company’s lead product candidate, AMP-224, is a first-in-class, orally-administered small molecule that is in development for the treatment of patients with myeloproliferative neoplasms (MPNs). MPNs are a group of blood cancers that affect the bone marrow and blood cells.
As of 2022, CanBas Co Ltd has a market cap of 10.31B. The company has a Return on Equity of -218.42%. CanBas Co Ltd is a company that manufactures and sells building materials. The company’s products include cement, concrete, bricks, and roof tiles. CanBas Co Ltd also provides construction services. The company was founded in 1934 and is headquartered in Tokyo, Japan.
Incyte Corporation reported strong financial results for the second quarter of FY2023, with total revenue reaching USD 954.6 million, an increase of 4.7% compared to the prior year. Net income was USD 203.6 million, up 26.1%. This is a positive sign for investors in Incyte Corporation, which indicates strong revenue growth, as well as improved efficiency and profitability. Going forward, investors should watch for further improvements in revenue, profitability, and overall management performance.